Impacts of bariatric surgery on costs and health outcomes of patients in Brazil: Interrupted time series analysis of multi-panel data

José Antonio Orellana Turri^{1,2,3}, Edmund Chada Baracat², José Maria Soares Júnior², Lionai Lima dos Santos⁵, Marco Aurélio Santo³, Flavia Mori Sarti^{1,4}, Nana Kwame Anokye⁶

Institutional affiliations

¹ Department of Nutrition in Public Health. Public Health Faculty, University of Sao Paulo.

² Department of Gynecology and Obstetrics. Central Institute of São Paulo Medical School, University of Sao Paulo.

³ Department of Gastroenterology, Digestive Disease Surgery. Clinics Hospital of Central Institute of Sao Paulo Medical School.

⁴ School of Arts, Sciences and Humanities. University of Sao Paulo.

⁵ Department of Physiotherapy. Sao Paulo State University Julio de Mesquita Filho.

⁶ Department of Clinical Sciences. College of Health and Life Sciences. Brunel University London.

Abstract

Study design: Original research

Obesity is one of the most important public health problems worldwide, presenting significant socioeconomic impacts in health systems. Considering the rising costs of health care and the escalating burden of obesity in diverse countries, there has been increasing trends in examination of cost-effectiveness of health interventions towards prevention and treatment of obesity and its effects on comorbidities. Bariatric surgery has been considered an effective intervention for reducing moderate to severe obesity and improvement of obesity-related morbidities.

Methodology: Interrupted Time-Series Analysis (ITSA) on costs and health outcomes from retrospective cohort of 114 patients who had bariatric surgery at the Hospital of Clinics from the University of Sao Paulo. Medical records encompassing complete data on anthropometric, hemodynamic and biochemical parameters, utilization of resources and costs for health care procedures and regular assessments of patients' health status associated with bariatric surgery at individual level were included in the study. Data on utilization of resources during outpatient and inpatient health care were used for estimation of patient's direct costs referring to bariatric surgery, and 6-month pre- and post-intervention periods, adopting health system perspective in micro-costing approach.

Results: Mean direct costs of hospitalization (-US\$2,762.22; -23.2%), image exams (-US\$7.53; -0.8%) and medication (-US\$175.37; -25.7%) presented decrease after bariatric surgery, and total

direct cost (US\$1,375.37; +138%), consultations (US\$0.42; +2.4%) and laboratory exams (US\$68.96; +63.4%) had increase. Reduction in weight, BMI, LDL, triglycerides, insulin, glucose-linked hemoglobin, and glucose showed improvements in patients' health status after bariatric surgery. Cholesterol, VLDL, and HDL presenting increase after surgery.

Conclusion: Bariatric surgery represents an effective intervention for treatment of moderate to severe obesity with extensive benefits regarding health promotion and reduction of burden of disease. Trends in direct costs and multiple health outcomes showed post-intervention improvements in patients' health status and reduction of health care needs of individuals.

Introduction

Obesity is one of the most important public health problems worldwide nowadays, presenting significant socioeconomic impacts in national health systems. Higher prevalence of obesity has been associated with augmented onset of type 2 diabetes mellitus (T2DM), hypertension, and early mortality. Increases in Body Mass Index (BMI) that characterize overweight and obesity are associated with higher need for and expenditures with medications, primarily for the treatment of hypertension, diabetes and cardiovascular disease.¹⁻⁹

Considering the rising costs of health care and the escalating burden of obesity in diverse countries, there has been increasing trends in examination of cost-effectiveness of health interventions towards prevention and treatment of obesity and its effects on comorbidities.¹⁰⁻¹⁵ Recent evidence on the impacts of obesity-related interventions, including prevention¹⁶⁻¹⁸ (promotion of physical activity and healthy eating) and treatment (medication and/or surgical procedures) strategies¹⁹⁻²⁴, have demonstrated that efficacy of bariatric surgery with multi-disciplinary approach decreasing body weight and improving of health including cancer, cardiovascular events, T2DM, dyslipidemia, life expectancy, and quality of life.^{5,23,25-28} in the long run.²⁹⁻³¹

Bariatric surgery has been considered an effective intervention for reducing moderate to severe obesity and improvement of obesity-related morbidities,³² being often used for its treatment in different countries, and has been included in the list of publicly funded procedures of some national health systems.¹⁶⁻¹⁸ Direct overall costs of bariatric surgery usually range from US\$25,000 to US\$30,000 per patient, and the annual health care costs for patients with BMI $\geq$ 35kg/m² generally vary between US\$3,000 to US\$10,000, in the treatment of T2DM, arterial hypertension and other.^{3,5,33-35}

Considering that obese individuals present approximately doubled risk for utilization of medical services in comparison to eutrophic individuals (RR 1.89; CI95% 1.88-1.89, $p < 0.001$), and mean annual medical costs are twofold higher in severe obesity (US\$1,140 per person) relative to the general population (US\$567 per person),³⁶ the bariatric surgery can lead to cost savings estimated

between US\$2,016 to US\$1,209 because of the decreased use of medication and reduction of events due to comorbidities.^{27,37}

In Brazil, bariatric surgery was included in the list of procedures for treatment of moderate to severe obesity and made accessible to the general population within the Brazilian Unified Health System (Sistema Unico de Saude, SUS) in 1999.^{38,39} There has been increasing trends in adoption of bariatric surgery throughout the public facilities, especially among young females³⁸, and results of previous studies have shown low mortality risk and high effectiveness of the surgery in the country.^{24,38,40–44}

To date, most studies focusing on assessment of costs and effectiveness of bariatric surgery in Brazil and other countries have been based on limited sample size and/or single health outcome^{5,6,23,38}, or relied on modelling of future outcomes. There is limited evidence including multiple anthropometric, hemodynamic and biochemical parameters of patients^{20,22,45}, especially using longitudinal data before and after bariatric surgery^{27,46}.

The absence of detailed information limits decision making around the use of bariatric surgery particularly given its high set up cost. In Brazil, there has been a significant increase in obesity rates in all age groups affecting in 2017 19% of the population. The Brazilian public health system offer freely bariatric surgery aiming to prevent possible complications related to obesity, but the lack of more accurate information about costs of the surgery, pre- and post-hospitalization and possible effectiveness can delay the spread of this procedure in the population.⁴⁷ Data information on multiple health outcomes associated with health care costs of bariatric surgery throughout pre-surgery period until follow-up at individual level may provide important information for public policy decision making; particularly considering data from high complexity hospital considered reference health care institution in Brazil.^{48–53}

The current study addresses the limitations in the literature by presenting an analysis of patient-level data in Brazil to examine the impact of bariatric surgery on multiple outcomes (including anthropometric, hemodynamic and biochemical parameters) using an interrupted time series approach. ITS is a useful quasi-experimental design for evaluation of longitudinal effects of interventions, especially based on natural experiments occurring in real-world settings.^{54–60}

Methodology

Study design

Interrupted Time-Series Analysis (ITSA) on costs and health outcomes from retrospective cohort of patients who had bariatric surgery at the Hospital of Clinics from the University of Sao Paulo (HC-FMUSP), Brazil, from January to December of 2018.

ITSA regression model uses time series of particular outcome of interest to establish an underlying trend, which is interrupted by an intervention at a given known point in time. The statistical design of the model draws an expected trend in the hypothetical scenario without the intervention, comparing with the new trend established post-intervention in order to identify potential differences. The post-intervention scenario provides a comparison for evaluation of the intervention impact by calculating the change in slope throughout time, according to the following standard equation:^{61,62}

$$Y_t = \beta_0 + \beta_1 \Delta t + \beta_2 X_t + \beta_3 X_t \Delta t + \varepsilon_t$$

Where Y_t is the accumulated result measured at each spaced time point t , Δt is the time since the start of the study, X_t is a dummy (indicator) variable representing the intervention (pre-intervention periods 0, or 1), and $X_t \Delta t$ is an interaction term.⁶²

Bariatric surgery characteristics

The patients included in the study were distributed in three groups of surgery: Roux-en-Y gastric by-pass (R-YGB), vertical gastrectomy, and adjustable gastric banding. In most cases, open surgery was performed; however, a minor proportion of patients had surgery performed using video laparoscopy.

According to the standard procedures of bariatric surgery in Brazil, there is assessment of patients' eligibility for bariatric surgery at primary health care facilities, and, depending on their health status, they are referred to a specialized health care unit. Patients with moderate to severe obesity diagnosis are referred to the Clinics Hospital, and included in the waiting list for bariatric surgery, performing pre-surgery monthly clinical and laboratory exams. After monitoring on eligibility criteria during variable period, patients are submitted to surgery, hospitalization and post-surgery follow-up, starting a post-surgical period of monthly clinic and laboratory exams (Figure 1).

Figure 1. Flowchart of processes performed by patients eligible for bariatric surgery. Sao Paulo (Brazil), 2020.

Obs.: BMI = Body mass Index; T2DM = type 2 diabetes mellitus; ICU = Intensive Care Unit.

Sample

Information on cohort of 114 patients who had bariatric surgery at the HC-FMUSP in Sao Paulo, Brazil, through the Brazilian Unified Health System (SUS) from January to December of 2018, were obtained from hospital's electronic medical records.

Only patients with medical records encompassing complete data on multiple anthropometric, hemodynamic and biochemical parameters, utilization of resources and costs for health care procedures and regular assessments of patients' health status associated with bariatric surgery at individual level within the period of 6 months pre- and post-intervention (bariatric surgery) were

included in the study.⁶³ Demographic and lifestyle characteristics of patients were also gathered to comprise control variables in statistical analysis, including: gender and age; tobacco use and alcohol consumption.

Considering Brazilian protocols for bariatric surgery within SUS, patients are required to perform numerous exams and consultations pre- and post-surgery on regular basis.³⁹ Individual information registered on daily-based electronic data collection at HC-FMUSP were gathered in single dataset referring to demographic and lifestyle characteristics, outpatient health care (pre- and post-intervention), and inpatient utilization of resources.

Variables

Information of patients during the periods 180 days (6-month) pre- and post-intervention were obtained considering the baseline date (Table 1).

Table 1. Information on health outcomes and resources utilization of patients. Sao Paulo (Brazil), 2018

Variable	Components
Health outcomes	Anthropometric measures (weight and height); Hemodynamic measures (blood pressure); Biochemical exams (cholesterol and fractions, triglycerides, insulin, glucose-linked hemoglobin, and fasting glucose).
Direct costs	Outpatient health care: <ul style="list-style-type: none"> • Appointments with health professionals; • Anthropometric measures (weight and height); • Hemodynamic exams (blood pressure); • Biochemical exams (cholesterol and fractions, triglycerides, insulin, glucose-linked hemoglobin, and fasting glucose). Inpatient health care: <ul style="list-style-type: none"> • Hospital length of stay; • Type of surgery; • Use of resources including: operating room, medication, meals, human resources, hemodynamic and biochemical exams.

The criteria adopted for comparison of health outcomes and costs was measurement of changes in relation to the baseline of intervention (first day of hospitalization for bariatric surgery).

Health outcomes

Information on health and nutritional status were obtained in electronic medical records of patients, referring to assessments pre- and post-surgery monitoring, considering its associations with bariatric surgery in the literature^{5,23,25-31}; therefore, comprising the following set of health outcomes adopted in statistical analysis:

- Weight (kg);
- BMI (kg/m²);
- Blood pressure (mmHg);
- Cholesterol (mg/dL);
- VLDL (mg/dL);
- LDL (mg/dL);
- HDL (mg/dL);
- Tryglicerides (mg/dL);
- Insulin (IU/mL);
- Glucose-linked haemoglobin (%);
- Fasting glucose (mg/dL)

Measures were performed according to standard procedures internationally adopted within HC-FMUSP facilities by trained health professionals.

Direct cost estimation

Data on utilization of resources during outpatient and inpatient health care were used for estimation of patient's direct costs referring to bariatric surgery, and 6-month pre- and post-intervention periods, adopting health system perspective in micro-costing approach.

Prices of inputs and wages of health professionals involved in procedures were obtained within institutional database, based on information on recent purchases registered and human resources payroll. Prices per item were multiplied by the amount used for treatment of the patient, and hourly wages were multiplied by the amount of time dedicated to procedures and consultations performed during each patient's treatment. Costs were updated to January 2020 and converted into US dollars using Brazilian Central Bank official exchange rate.

Statistical analysis

Descriptive statistics and interrupted time series analysis (ITSA) with generalized estimating equations (GEE) and marginal effects were performed using single-center retrospective data on costs and multiple health outcomes related to bariatric surgery in patients from the HC-FMUSP. Information gathered for each patient was split into two segments for analysis, i.e., health outcomes and direct costs of health care before and after bariatric surgery, respectively.⁶³

GEE with varying distribution were fitted for the different outcomes as follow: pre-intervention, intervention, post-intervention (gender and age) for adjustment of monthly trends according to patients' characteristics. Marginal effects were obtained after GEE estimation by sample means at

each period of evaluation (pre and post intervention) and are used for the incremental cost and effects over each outcome evaluated.

Dependent variables included in the models were direct costs of health care and health outcomes (weight, BMI, blood pressure, cholesterol and fractions, triglycerides, insulin, glucose-linked hemoglobin, and fasting glucose).

Interrupted time series ordered logistic were estimated for health outcomes, and Poisson models were estimated for health care costs, controlling for age and gender with random effects estimator. The interrupted time series model was achieved by defining independent variables Δt = time point (1,2,3,4,5,6,7,8,9,10,11,12,13), $X_t=0$ for time points in stage 1 (time points 1, 2, 3, 4, 5 and 6) and 1 for time points in stage 2 (time points 7, 8, 9, 10, 11, 12 and 13), and $(XT)_t=0$ for time points in stage 1, and $(t-4)$ for time points in stage 2.

The regression coefficient for T_t represents the rate of change of activity in stage 1, and the sum of regression coefficients for T_t and $(XT)_t$ is the rate of change of activity in stage 2. The effect over time was defined as the difference in the rate of change from stage 1 to stage 2, that is, the regression coefficient of $(XT)_t$.

The immediate effect of the intervention was defined as the regression coefficient corresponding to X_t (corresponding to the counterfactual difference between stage 1 and stage 2 evaluated at time point 7). The interrupted series time model for all costs and obesity-related measures was an ordinal logistic repeated measures model, including additive effects for T_t , X_t and $(XT)_t$, and for all covariates to be adjusted for.

Statistical analysis were conducted using Stata version 14, and Newey-West standard errors were reported to account for autocorrelation at lag 1.⁵⁹

Patient and Public Involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Ethical aspects

The study was approved by the Ethical Committee of the School of Medicine and Faculty of Public Health from the University of Sao Paulo (opinion numbers 0844918.6.3001.0068 and 90844918.6.0000.5421).

Results

Characteristics pre- and post-surgery

Data included information from 114 patients who had bariatric surgery in HC-FMUSP during 2018. Patients were previously enrolled in the waiting list for bariatric surgery at the hospital, and therefore were followed at least 180 days before and 180 days after the bariatric surgery. Considering characteristics at baseline, patients were approximately 48 years-old and the majority were female. Small proportion of individuals were smokers and most patients had comorbidities, especially hypertension and/or diabetes. The type of surgery conducted in most cases was open Y-Roux gastric by-pass (Table 2).

Table 2. Baseline characteristics of bariatric surgery patients. Sao Paulo (Brazil), 2018

Gender		N	(%)
Men		9	7.9%
Women		95	83.3%
Age ($\mu \pm SD$)		47.8 $\pm$ 14.1	
Lifestyle characteristics			
Tobacco use		20	17.5%
Alcohol consumption		0	0.0%
Comorbidity			
Hypertension		72	63.2%
T2DM		67	58.8%
Sleep apnea		31	27.2%
Dyslipidemia		25	21.9%
Arthrosis		25	21.9%
Hypothyroidism		10	8.8%
Varices		10	8.8%
Chronic renal insufficiency		10	8.8%
Cardiac Congestive Insufficiency		5	4.4%
Type of surgery			
Y-Roux gastric by-pass	Open	67	58.8%
	Video laparoscopic	34	29.8%
Sleeve (vertical gastrectomy)	Open	4	3.5%
	Video laparoscopic	3	2.6%
Adjustable gastric banding	Open	3	2.6%
	Video laparoscopic	3	2.6%

Obs.: μ = mean; SD = standard deviation; T2DM = type 2 diabetes mellitus

Mean direct costs of hospitalization (-US\$2,762.22; -23.2%), image exams (-US\$7.53; -0.8%) and medication (-US\$175.37; -25.7%) presented decrease after bariatric surgery, and total direct cost (US\$1,375.37; +138%), consultations (US\$0.42; +2.4%) and laboratory exams (US\$68.96; +63.4%) had increase in the same period, especially due to need of patients' follow-up after intervention.

Regarding health outcomes, there were few obesity-related exams presenting increase after surgery (cholesterol, VLDL, and HDL); however, increase in HDL represents an improvement in health status. Similarly, reduction in weight, BMI, LDL, triglycerides, insulin, glucose-linked hemoglobin, and glucose showed improvements in patients' health status after bariatric surgery (Table 3).

Table 3. Health outcomes and direct costs of patients during 6-month pre- and post-bariatric surgery. Sao Paulo (Brazil), 2018

Health outcomes	6-month period		Difference		Difference (US\$)	Cost per unit change (US\$)
	Pre-surgery μ ($\pm$ SD)	Post-surgery μ ($\pm$ SD)	Mean	%		
Weight (kg)	125.53 ($\pm$ 18.58)	103.23 ($\pm$ 24.46)	-22.3	-17.8%	22.3	61.68
BMI (kg/m ²)	47.36 ($\pm$ 4.22)	39.01 ($\pm$ 7.26)	-8.35	-17.6%	8.35	164.71
Blood pressure (mmHg)	132 ($\pm$ 15.21)	126.51 ($\pm$ 17.36)	-5.49	-4.2%	5.49	250.52
Cholesterol (mg/dL)	165.11 ($\pm$ 39.9)	167.78 ($\pm$ 38.55)	2.67	1.6%	2.67	515.12
VLDL (mg/dL)	21.51 ($\pm$ 8.33)	22.91 ($\pm$ 8.93)	1.4	6.5%	1.4	982.41
LDL (mg/dL)	94.06 ($\pm$ 34.66)	93.2 ($\pm$ 34.58)	-0.86	-0.9%	0.86	1599.27
HDL (mg/dL)	45.63 ($\pm$ 14.38)	51.88 ($\pm$ 13.23)	6.25	13.7%	6.25	220.06
Tryglicerides (mg/dL)	130.67 ($\pm$ 64.21)	117.27 ($\pm$ 56.95)	-13.4	-10.3%	13.4	102.64
Insulin (IU/mL)	17.19 ($\pm$ 22.55)	12.69 ($\pm$ 7.47)	-4.5	-26.2%	4.5	305.64
Glucose-linked haemoglobin (%)	127.57 ($\pm$ 43.88)	113.61 ($\pm$ 36.47)	-13.96	-10.9%	13.96	98.52
Fasting glucose (mg/dL)	113.22 ($\pm$ 45.77)	99.11 ($\pm$ 39.83)	-14.11	-12.5%	14.11	97.47
Health care costs	6-month period		Difference		Difference US\$	Cost per unit change
	Pre-surgery μ ($\pm$ SD)	Post-surgery μ ($\pm$ SD)	Mean	%		
Consultations	17.64 ($\pm$ 13.9)	18.06 ($\pm$ 15.32)	0.42	2.4%	0.42	3274.69
Inpatient days	11913.26 ($\pm$ 12682.01)	9151.04 ($\pm$ 9695.16)	-2762.22	-23.2%	2762.22	0.50
Laboratory exams	108.72 ($\pm$ 112.94)	177.68 ($\pm$ 217.78)	68.96	63.4%	68.96	19.94
Image exams	888.99 ($\pm$ 901.22)	881.46 ($\pm$ 854.78)	-7.53	-0.8%	7.53	182.65
Medication	683.9 ($\pm$ 854.73)	508.45 ($\pm$ 696.99)	-175.45	-25.7%	175.45	7.84
Total direct costs	996.61 ($\pm$ 4515.39)	2371.98 ($\pm$ 6172.79)	1375.37	138.0%	1375.37	-

Obs.: μ = mean; SD = standard deviation. *Including the cost of bariatric surgery

Changes pre- and post-intervention using ITSA

Referring to results of the interrupted time series analysis, there was rise in overall costs at the period of intervention due to high costs of the bariatric surgery; however, it was followed by statistically significant decrease post-intervention. In general, post-surgery changes of health outcomes were also statistically significant, except cholesterol and LDL, showing improvements of patients' health status after intervention (Table 4).

Table 4. Pre- and post-intervention scenario of bariatric surgery using ITSA. Sao Paulo (Brazil), 2018

Health outcomes	Cons	Pre	Int	Post	p
Weight	133.7986	0.0053	-15.7546	-0.0324	<0.001
BMI	53.6564	-0.0024	4.4470	-0.0158	<0.001
Blood pressure	132.7641	-0.0024	0.4449	-0.0061	<0.001
Cholesterol	157.4912	-0.0170	7.1876	0.0186	0.005
VLDL	19.3720	0.0043	3.1873	-0.0124	<0.001
LDL	93.4065	-0.0093	9.2046	-0.0080	0.012
HDL	33.0861	0.0212	-8.5178	-0.0024	<0.001
Triglycerides	108.6332	0.0231	0.4112	-0.0775	<0.001
Insulin	8.9126	0.0238	-10.2879	-0.0296	<0.001
Glucose-linked haemoglobin	122.9973	0.0038	-3.6614	-0.0326	<0.001
Fasting glucose	90.3722	0.0343	-6.2629	-0.0836	<0.001
Health care costs	Cons	Pre	Int	Post	p
Direct costs	228.2564	0.8666	4700.7260	-10.2396	<0.001

Obs.: cons = constant; pre = pre-intervention; int = intervention; post = post-intervention.
Regression with Newey-West standard errors

Post-intervention linear trends

Trends in post-intervention health outcomes showed reduction in most parameters, except cholesterol and HDL. In the case of HDL, increase in concentration indicates improvement in health status; whereas in the case of cholesterol, positive trend post-intervention was not statistically significant. BMI, VLDL, HDL, and fasting glucose showed important changes in trends pre- and post-surgery. Regarding direct costs, there was not a clear trend considering the 180-day period pre- and post-intervention (Table 5 and Figure 1).

Table 5. Post-intervention trends of health outcomes of bariatric surgery. Sao Paulo (Brazil), 2018

Health outcomes	Trend	CI 95%	p
Weight	-6.2992	(-0.0356;-0.0187)	<0.001
BMI	-9.3199	(-0.022;-0.0143)	<0.001
Blood pressure	-3.0299	(-0.0141;-0.003)	0.0025
Cholesterol	0.2094	(-0.0135;0.0168)	0.8341
VLDL	-4.9564	(-0.0114;-0.0049)	<0.001
LDL	-2.4414	(-0.0312;-0.0034)	0.0147
HDL	7.7052	(0.014;0.0236)	<0.001
Triglycerides	-4.0045	(-0.0812;-0.0278)	<0.001
Insulin	-3.5947	(-0.009;-0.0027)	<0.001
Glucose-linked hemoglobin	-3.4181	(-0.0453;-0.0123)	0.001
Fasting glucose	-5.0545	(-0.0683;-0.0301)	<0.001

Obs.: CI 95% = 95% confidence interval.
Regression with Newey-West standard errors.

Figure 1. Trends of direct costs and health outcomes (laboratory exams) of bariatric surgery using ITSA for 180-day period pre- and post-intervention. Sao Paulo (Brazil), 2018

In addition, results of the generalized estimating multivariate regression showed that most changes observed in the comparison between pre- and post-surgery remain statistically significant controlling for patients' characteristics. Marginal effects in direct health care costs post-intervention including covariates were significantly negative, similarly to health outcomes referring to blood pressure, VLDL, triglycerides, insulin, glucose-linked hemoglobin, and fasting glucose (Table 6).

Table 6. Marginal effects during pre-intervention, intervention, post-intervention adjusted by gender and age using GEE. Sao Paulo (Brazil), 2018

Health Outcomes	Characteristics	dy/dx	CI95%	p
BMI	Pre	0.003	(0.001 – 0.005)	<0.001
	Int	0.803	(0.006-0.154)	0.033
	Post	-0.0006	(-0.0008—0.0004)	<0.001
	Gender (female)	-0.005	(-0.034—0.024)	0.744
	Age	0.0007	(2.855-3.001)	0.105
Weight	Pre	0.002	(-0.01-0.01)	0.804
	Int	-58.404	(-69.9-46.9)	<0.001
	Post	0.086	(0.06-0.1)	<0.001
	Gender (female)	-4.286	(-5.29-3.27)	<0.001
	Age	-0.12	(-0.15-0.08)	<0.001
Blood pressure	Pre	-0.002	(-0.005-0.001)	0.167
	Int	0.522	(-1.66-2.71)	0.640
	Post	-0.006	(-0.01-0.001)	0.007
	Gender (female)	0.221	(-1.6-2.04)	0.812
	Age	0.007	(-0.04-0.06)	0.808
Cholesterol	Pre	-0.03	(-0.04-0.01)	<0.001
	Int	6.047	(-0.78-12.87)	0.083
	Post	0.046	(0.03-0.06)	<0.001
	Gender (female)	9.214	(7.43-10.98)	<0.001
	Age	0.121	(0.06-0.17)	<0.001
VLDL	Pre	0.007	(0.003-0.01)	<0.001
	Int	1.784	(0.14-3.42)	0.033
	Post	-0.014	(-0.01;-0.01)	<0.001
	Gender (female)	-0.108	(-0.75-0.54)	0.744
	Age	0.016	(-0.003-0.03)	0.105
LDL	Pre	-0.017	(-0.02-0.006)	0.002
	Int	-1.776	(-7.95-4.39)	0.573
	Post	0.033	(0.01-0.04)	<0.001
	Gender (female)	6.900	(5.58-8.21)	<0.001
	Age	-0.039	(-0.07-0.0001)	0.049
HDL	Pre	0.022	(0.01-0.02)	<0.001
	Int	-8.427	(-10.16-6.69)	<0.001
	Post	-0.005	(-0.008-0.0006)	0.023
	Gender (female)	1.125	(0.14-2.1)	0.024
	Age	0.092	(0.06-0.12)	<0.001
Triglycerides	Pre	0.051	(0.04-0.06)	<0.001
	Int	-6.802	(-11.98-1.61)	0.01
	Post	-0.111	(-0.12-0.09)	<0.001
	Gender (female)	6.805	(5.27-8.33)	<0.001
	Age	0.18	(0.13-0.22)	<0.001
Insulin	Pre	0.014	(0.01-0.01)	<0.001
	Int	-7.207	(-9.05-5.35)	<0.001
	Post	-0.017	(-0.02-0.01)	<0.001
	Gender (female)	0.207	(-0.3-0.71)	0.427
	Age	-0.001	(-0.01-0.01)	0.885
Glucose-linked hemoglobin	Pre	0.013	(0.003-0.02)	0.007
	Int	-3.227	(-8.41-1.96)	0.223
	Post	-0.051	(-0.06-0.03)	<0.001
	Gender (female)	4.468	(2.96-5.97)	<0.001
	Age	-0.011	(-0.05-0.03)	0.643
Fasting glucose	Pre	0.019	(0.006-0.03)	0.003
	Int	8.873	(1.76-15.98)	0.014
	Post	-0.095	(-0.11-0.07)	<0.001
	Gender (female)	6.721	(5.37-8.06)	<0.001
	Age	0.119	(0.07-0.15)	<0.001
Health Care Costs	Characteristics	dy/dx	CI95%	p
Direct cost	Pre	1.153	(1.12-1.17)	<0.001
	Int	1189.518	(1179.29-1199.74)	<0.001
	Post	-4.323	(-4.35-4.29)	<0.001
	Gender (female)	-100.838	(-103.32-98.34)	<0.001
	Age	1.303	(1.22-1.38)	<0.001

Obs.: pre = pre-intervention; int = intervention; post = post-intervention.

Discussion

Moderate to severe obesity impose important socioeconomic and health burden on individuals, health systems and societies worldwide; therefore, its prevention and treatment may represent substantial impacts on health status, quality of life and utilization of health care resources. Results presented in the study showed reduction in direct health care costs and improvements in multiple health outcomes of cohort of patients who had bariatric surgery in a reference hospital within Brazilian health system, comparing 180-day period pre- and post-intervention through interrupted time series analysis with GEE, including controls for individual characteristics.

In addition, micro-costing technique allowed to identify main health care cost drivers pre- and post-surgery in high complexity institution from the public sector in Brazil. Although there was an initial rise in overall health care costs during the period of bariatric surgery, post-intervention trends were significantly negative.

Pre-intervention results allowed the analysis of cumulative health care costs related to procedures related to comorbidities and monitoring during waiting list for bariatric surgery. Data from health outcomes showed worsening of patients' health status regarding main comorbidities during the period before the intervention, especially weight gain, hypertension, type 2 diabetes, and dyslipidemia.^{23,64}

Lopes et al., in a systematic review and meta-analysis has found that there is important decline in drug prescription and health expenditure related to comorbidity resolution of several obesity-related diseases like arterial hypertension and T2DM. The prevalence of arterial hypertension improved 78% and T2DM improved 92%. In the same study, the authors found that anti-hyperglycemic medication have been discontinued in 93% of diabetic patients after surgery and anti-hypertensive drugs were able to be discontinued in 35% of patients and reduced in 48%.⁶⁴ Similarly, Sussenbach et al., have found resolution of comorbidities like T2DM, arterial hypertension and dyslipidemia higher than 95% at 36 months after surgery, with important reduction in the medical costs in the course of the post-operative period, in relation to expenses for medications, professional care, and examinations in the preoperative period.⁴¹

Considering results obtained in post-surgery health outcomes, there was improvement of patients' health status, especially referring to parameters related to diabetes and hypertension. Evidence from previous studies indicate that bariatric surgery for treatment of moderate to severe usually improves general health conditions and quality of life of patients, including control and reduction of effects from comorbidities like hypertension and diabetes, at relatively low cost to the public health system.^{15,65}

The mean cost for each unit of decreased obesity health-related outcome was quite reasonable in terms of public health system. The cost of US\$ 61.68 per kg of weight loss and above US\$ 100 to

T2DM biomarkers like glucose-linked haemoglobin and fasting glucose to one unit of decrease, the bariatric surgery shows costs relatively above the drug therapy. In our country, the annual expenditure per patient with treatment for T2DM with medicines reach US\$ 259.36 and in the rest of the world range from US\$ 1.937 to US\$ 13.243 or US\$ 63.722 in 35-year lifetime.^{6,33,66–68}

Considering cardiovascular risk, which is high related to very expensive costs to health systems, our study has found costs from US\$ 102.64 to US\$ 982.41 (for triglycerides and Vldl, respectively) per one unit of fall in the blood exam. In our country, the average annual cost in medicines for dyslipidemia is US\$ 1.417 to US\$ 2.300 and the nutritional and laboratory follow-up is nearly US\$ 848.⁴¹ The data found in our study can be also considered at very low cost, mainly take in place the long-term benefit of reduction on the risk of mortality, morbidity, and high cost.^{69,70}

Cholesterol was the only biochemical marker showing different pattern from expected; however, it was also not statistically significant. Otherwise, the results confirm trends in enhancement of patients' health status and reduction in overall health care costs post-bariatric surgery, after controlling for patients' characteristics.¹⁵

To date, traditional observational studies perform assessment of costs involved in procedures and/or measurement of effectiveness of bariatric surgery using mean pre- and post-intervention data for comparison of few health outcomes. However, it comprises an approach that neglects the identification of trends in patients' costs and/or health outcomes during pre- and post-surgery at individual level.

The present study provides information with additional precision on impacts of bariatric surgery considering direct costs and multiple health outcomes related to comorbidities of moderate to severe obesity. The ITS and GEE modelling approaches allowed to assess marginal effects of bariatric surgery in evolution of costs and health outcomes, including correction for individual-level characteristics which reduces potential bias of estimation.

Therefore, our results suggest potential causal relationship between bariatric surgery and improvement of health outcomes in patients with severe to moderate obesity. Considering that patients were followed during similar periods before (waiting list) and after (follow-up) bariatric surgery for comparison of information pre- and post-intervention, we obtained robust results indicating that bariatric surgery was efficient intervention to interrupt worsening of patients' health conditions, and to promote improvements in health outcomes related to hypertension and diabetes in association with reduction of direct health care costs after treatment, findings in accordance with previous evidence.^{15,19–21,23,24}

Due to lack of previous evidence regarding impacts of bariatric surgery based on pre- and post-intervention costs and multiple health outcomes using micro-costing approach at individual-level, the robust results provided by our estimates may provide real-world foundations for public policy

decision making within Brazilian national health system, especially referring to intervention with significant potential for reduction of burden of diseases related to obesity.^{71,72}

The analysis was conducted on small sample of patients with moderate to severe obesity within one Brazilian hospital of reference who were on the waiting list for bariatric surgery, followed from 6-month period before and after the bariatric surgery, extracted from a cohort of approximately 2,000 patients followed during 12 or more years. The selection of sample for analysis using the interrupted time series analysis with GEE was based on eligibility of patients, considering the existence of complete information registered in electronic medical records encompassing periods pre- and post-intervention and the need for micro-costing approach using data obtained manually for each patient. However, in view of promising results obtained through application of the statistical strategy for assessment of trends regarding direct health care costs and health outcomes, additional information may be obtained for further investigation of the subject.

Conclusion

Bariatric surgery represents an effective intervention for treatment of moderate to severe obesity with extensive benefits regarding health promotion and reduction of burden of disease. Trends in direct costs and multiple health outcomes showed post-intervention improvements in patients' health status and reduction of health care needs of individuals.

Acknowledgements

The study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code001 - 88887.368403/2019-00.

The authors also thank the contributions from the Department of Gastroenterology, the Department of Obstetrics and Gynecology, the Hospital of Clinics (HC-FMUSP), Mr. Vilson Cobello Júnior (Coordinator of Technology of Information at HC-FMUSP), and Mr. Jacson Venâncio de Barros (Director of Informatics Department of the Brazilian Public Health System, DATASUS).

Conflicts of interest

The authors declare that there is no conflict of interests in the design, execution and publication of the study.

Data availability statement

The data that support the findings of this study are available from the corresponding author JAOT, upon reasonable request. Restrictions apply to the availability of patients' medical datasheet, which were used under hospital permission for this study.

References

1. Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric Surgery: Shedding the Monetary Weight of Prescription Costs in the Managed Care Arena. *Obes Surg*. 2004;14(6):725-730. doi:10.1381/0960892041590999
2. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309(1):71-82. doi:10.1001/jama.2012.113905
3. Health Quality Ontario HQ. Bariatric surgery: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2005;5(1):1-148. <http://www.ncbi.nlm.nih.gov/pubmed/23074460>. Accessed January 19, 2017.
4. The GBD 2015 Obesity Collaborators, The GBD 2015 Obesity Collaborators*. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *n engl j med*. 2017;377(1):13-27. doi:10.1056/NEJMoa1614362
5. Warren JA, Ewing JA, Hale AL, Blackhurst DW, Bour ES, Scott JD. Cost-effectiveness of Bariatric Surgery: Increasing the Economic Viability of the Most Effective Treatment for Type II Diabetes Mellitus. *Am Surg*. 2015;81(8):807-811. <http://www.ncbi.nlm.nih.gov/pubmed/26215244>. Accessed July 28, 2016.
6. Yee M, Leung M, Carlsson NP, Colditz GA, Chang S-H. The Burden of Obesity on Diabetes in the United States: Medical Expenditure Panel Survey, 2008 to 2012. *Value Heal*. 2017;20:77-84. doi:10.1016/j.jval.2016.08.735
7. Rtveldadze K, Marsh T, Webber L, et al. Health and Economic Burden of Obesity in Brazil. *PLoS One*. 2013;8(7). doi:10.1371/journal.pone.0068785
8. Turi BC, Codogno JS, Santi FM, Anokye NK, Fernandes RA. Determinants of outpatient expenditure within primary care in the Brazilian National Health System Determinantes de gastos ambulatoriais na atenção primária do sistema público de saúde brasileiro. 2017;135(3):205-212. doi:10.1590/1516-3180.2016.0224141116
9. Ishimori N, Shimada YJ, Kuno T, Tanimoto E, Morita S. Effects of Bariatric Surgery on Cardiovascular Disease: A Concise Update of Recent Advances. *Front Cardiovasc Med* / www.frontiersin.org. 2019;1:94. doi:10.3389/fcvm.2019.00094
10. Elbanna A, Eldin MT, Fathy M, et al. Bariatric Bypass Surgery to Resolve Complicated Childhood Morbid Obesity: Case Report Study. *Medicine (Baltimore)*. 2015;94(49):e2221. doi:10.1097/MD.0000000000002221
11. Karim MA, Clifton E, Ahmed J, Mackay GW, Ali A. Economic evaluation of bariatric surgery to combat morbid obesity: A study from the West of Scotland. *Asian J Endosc Surg*. 2013;6(3):197-202. doi:10.1111/ases.12042

12. Dee A, Kearns K, O'Neill C, et al. The direct and indirect costs of both overweight and obesity: a systematic review. *BMC Res Notes*. 2014;7:242. doi:10.1186/1756-0500-7-242
13. Finkelstein EA, Strombotne KL, Zhen C, Epstein LH. Food prices and obesity: a review. *Adv Nutr*. 2014;5(6):818-821. doi:10.3945/an.114.007088
14. Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. *Obes Rev*. 2011;12(2):131-141. doi:10.1111/j.1467-789X.2009.00712.x
15. Powers KA, Rehrig ST, Jones DB, Jones DB. Financial Impact of Obesity and Bariatric Surgery. *Med Clin North Am*. 2007;91(3):321-338. doi:10.1016/J.MCNA.2007.01.001
16. Specchia ML, Veneziano MA, Cadeddu C, et al. Economic impact of adult obesity on health systems: a systematic review. *Eur J Public Health*. 2015;25(2):255-262. doi:10.1093/eurpub/cku170
17. Rtveladze K, Marsh T, Barquera S, et al. Obesity prevalence in Mexico: impact on health and economic burden. *Public Health Nutr*. 2014;17(1):233-239. doi:10.1017/S1368980013000086
18. Breyer F, Bundorf MK. Chapter Eleven – Health Care Spending Risk, Health Insurance, and Payment to Health Plans. In: *Handbook of Health Economics*. Vol 2. ; 2011:691-762. doi:10.1016/B978-0-444-53592-4.00011-6
19. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis. *J Am Med Assoc*. 2004;292(14):1724-1737. doi:10.1001/jama.292.14.1724
20. Moussa O, Ardissino M, Heaton T, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. doi:10.1093/eurheartj/ehaa069
21. Wang BCM, Wong ES, Alfonso-Cristancho R, et al. Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity. *Eur J Heal Econ*. 2014;15(3):253-263. doi:10.1007/s10198-013-0472-5
22. Wu T, Wong SKH, Law BTT, et al. Five-year effectiveness of bariatric surgery on disease remission, weight loss, and changes of metabolic parameters in obese patients with type 2 diabetes: A population-based propensity score-matched cohort study. *Diabetes Metab Res Rev*. 2020;36(3):e3236. doi:10.1002/dmrr.3236
23. Raaijmakers LCH, Pouwels S, Thomassen SEM, Nienhuijs SW. Quality of life and bariatric surgery: a systematic review of short- and long-term results and comparison with community norms. *Eur J Clin Nutr*. 2017;71(4):441-449. doi:10.1038/ejcn.2016.198
24. Assumpção RP, Bahia LR, da Rosa MQM, et al. Cost-Utility of Gastric Bypass Surgery Compared to Clinical Treatment for Severely Obese With and Without Diabetes in the Perspective of the Brazilian Public Health System. *Obes Surg*. June 2019:1-10.

- doi:10.1007/s11695-019-03957-7
25. Rezende LFM de, Arnold M, Rabacow FM, et al. The increasing burden of cancer attributable to high body mass index in Brazil. *Cancer Epidemiol.* 2018;54:63-70.
doi:10.1016/J.CANEP.2018.03.006
 26. Dillon C, Peddle J, Twells L, et al. Rapid Reduction in Use of Antidiabetic Medication after Laparoscopic Sleeve Gastrectomy: The Newfoundland and Labrador Bariatric Surgery Cohort (BaSCo) Study. *Can J Hosp Pharm.* 2015;68(2):113-120.
<http://www.ncbi.nlm.nih.gov/pubmed/25964682>. Accessed July 29, 2016.
 27. Makary MA, Clark JM, Shore AD, et al. Medication Utilization and Annual Health Care Costs in Patients With Type 2 Diabetes Mellitus Before and After Bariatric Surgery. *Arch Surg.* 2010;145(8):726. doi:10.1001/archsurg.2010.150
 28. Schaan Casagrande D, Dornelles Rosa D, Umpierre D, Aguiar Sarmiento R, Garcia Rodrigues C, Schaan BD. Incidence of Cancer Following Bariatric Surgery: Systematic Review and Meta-analysis. *Obes Rev.* 2014.
 29. Biener AI, Cawley J, Meyerhoefer C. The medical care costs of obesity and severe obesity in youth: An instrumental variables approach. *Health Econ.* 2020;29(5):624-639.
doi:10.1002/hec.4007
 30. Gulliford MC, Charlton J, Prevost T, et al. Costs and Outcomes of Increasing Access to Bariatric Surgery: Cohort Study and Cost-Effectiveness Analysis Using Electronic Health Records. 2017. doi:10.1016/j.jval.2016.08.734
 31. Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery. *N Engl J Med.* 2004;351(26):2683-2693.
doi:10.1056/NEJMoa035622
 32. Czernichow S, Moszkowicz D, Szwarcensztein K, et al. Impact of Bariatric Surgery on the Medical Management and Costs of Obese Patients in France: an Analysis of a National Representative Claims Database. *Obes Surg.* 2015;25(6):986-996. doi:10.1007/s11695-014-1488-3
 33. Tang Q, Sun Z, Zhang N, et al. Cost-Effectiveness of Bariatric Surgery for Type 2 Diabetes Mellitus: A Randomized Controlled Trial in China. *Medicine (Baltimore).* 2016;95(20):e3522. doi:10.1097/MD.00000000000003522
 34. Banerjee S, Garrison LP, Flum DR, Arterburn DE, Arterburn DE. Cost and Health Care Utilization Implications of Bariatric Surgery Versus Intensive Lifestyle and Medical Intervention for Type 2 Diabetes. *Obesity.* 2017;25(9):1499-1508. doi:10.1002/oby.21927
 35. Anselmino M, Bammer T, Fernández Cebrián JM, Daoud F, Romagnoli G, Torres A. Cost-effectiveness and Budget Impact of Obesity Surgery in Patients with Type 2 Diabetes in

- Three European Countries(II). *Obes Surg.* 2009;19(11):1542-1549. doi:10.1007/s11695-009-9946-z
36. Keating CL, Neovius M, Sjöholm K, et al. Healthcare Utilization and Costs in Severely Obese Subjects Before Bariatric Surgery. *Obesity.* 2012;20(12):2412-2419. doi:10.1038/oby.2012.124
 37. El Chaar M, Claros L, Ezeji GC, Miletics M, Stoltzfus J. Improving Outcome of Bariatric Surgery: Best Practices in an Accredited Surgical Center. *Obes Surg.* 2014;24(7):1057-1063. doi:10.1007/s11695-014-1209-y
 38. Carvalho A da S, Rosa RDS. Cirurgias bariátricas realizadas pelo Sistema Único de Saúde no período 2010-2016: estudo descritivo das hospitalizações no Brasil. *Epidemiol e Serv saude Rev do Sist Unico Saude do Bras.* 2019;28(1):e2018260. doi:10.5123/S1679-49742019000100023
 39. Ministério da Saúde.
http://bvsms.saude.gov.br/bvs/saudelegis/gm/2013/prt0425_19_03_2013.html. Accessed April 17, 2020.
 40. Salgado Júnior W, Pitanga KC, Santos JS dos, Sankarankutty AK, Silva Jr O de C e, Ceneviva R. Costs of bariatric surgery in a teaching hospital and the financing provided by the Public Unified Health System. *Acta Cir Bras.* 2010;25(2):201-205. doi:10.1590/S0102-86502010000200014
 41. Sussenbach SP, Padoin A V., Silva EN, et al. Economic Benefits of Bariatric Surgery. *Obes Surg.* 2012;22(2):266-270. doi:10.1007/s11695-011-0558-z
 42. Sussenbach SP, Silva EN, Pufal MA, Casagrande DS, Padoin AV, Mottin CC. Systematic review of economic evaluation of laparotomy versus laparoscopy for patients submitted to Roux-en-Y gastric bypass. *PLoS One.* 2014;9(6):e99976. doi:10.1371/journal.pone.0099976
 43. Miott MS, Koike MK, Miott MS, Koike MK. Bariatric surgery. Analysis of hospital admissions for obesity in the Brazilian Public Health System (SUS) in Sao Paulo. *Acta Cir Bras.* 2014;29(11):759-764. doi:10.1590/S0102-86502014001800011
 44. Zubiaurre PR, Bahia LR, da Rosa MQM, et al. Estimated Costs of Clinical and Surgical Treatment of Severe Obesity in the Brazilian Public Health System. *Obes Surg.* 2017;27(12):3273-3280. doi:10.1007/s11695-017-2776-5
 45. Zhou X, Yu J, Li L, et al. Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis. *Obes Surg.* 2016;26(11):2590-2601. doi:10.1007/s11695-016-2144-x
 46. Doumouras AG, Saleh F, Anvari S, Gmora S, Anvari M, Hong D. A Longitudinal Analysis of Short-Term Costs and Outcomes in a Regionalized Center of Excellence Bariatric Care

- System. *Obes Surg.* 2017;27(11):2811-2817. doi:10.1007/s11695-017-2707-5
47. Tonatto-Filho AJ, Gallotti FM, Chedid MF, Grezzana-Filho T de JM, Garcia AMSV. Bariatric surgery in Brazilian public health system: The good, the bad and the ugly, or a long way to go. yellow sign. *Arq Bras Cir Dig.* 2019;32(4). doi:10.1590/0102-672020190001e1470
48. Maciejewski ML, Arterburn DE. Cost-effectiveness of bariatric surgery. *JAMA.* 2013;310(7):742-743. doi:10.1001/jama.2013.276131
49. Arterburn D, Maciejewski M, Tsevat J. Impact of morbid obesity on medical expenditures in adults. *Int J Obes.* 2005;29:334-339. doi:10.1038/sj.ijo.0802896
50. Maciejewski ML, Smith VA, Livingston EH, et al. Health Care Utilization and Expenditure Changes Associated With Bariatric Surgery. *Med Care.* 2010;48(11):989-998. doi:10.1097/MLR.0b013e3181ef9cf7
51. Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. *Acad Pediatr.* 2013;13(6 SUPPL.). doi:10.1016/j.acap.2013.08.002
52. Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int J Epidemiol.* 2017;348-355. doi:10.1093/ije/dyw098
53. Linden A. Using randomization tests to assess treatment effects in multiple-group interrupted time series analysis. *J Eval Clin Pract.* 2019;25(1):5-10. doi:10.1111/jep.12995
54. Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based quasi-experimental approach when randomisation is not an option: Interrupted time series analysis. *BMJ.* 2015;350. doi:10.1136/bmj.h2750
55. Wong RH, Smieliauskas F, Pan IW, Lam SK. Interrupted time-series analysis: Studying trends in neurosurgery. *Neurosurg Focus.* 2015;39(6):1-5. doi:10.3171/2015.9.FOCUS15374
56. Lopez Bernal J, Cummins S, Gasparrini A. The use of controls in interrupted time series studies of public health interventions. *Int J Epidemiol.* 2018;47(6):2082-2093. doi:10.1093/ije/dyy135
57. Lopez Bernal J, Soumerai S, Gasparrini A. A methodological framework for model selection in interrupted time series studies. *J Clin Epidemiol.* 2018;103:82-91. doi:10.1016/j.jclinepi.2018.05.026
58. Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: Systematic review and recommendations. In: *Journal of Clinical Epidemiology.* Vol 68. Elsevier USA; 2015:950-956. doi:10.1016/j.jclinepi.2014.12.018
59. Linden A, Yarnold PR. Using machine learning to evaluate treatment effects in multiple-

- group interrupted time series analysis. *J Eval Clin Pract.* 2018;24(4):740-744.
doi:10.1111/jep.12966
60. Valsamis EM, Husband H, Chan GKW. Segmented Linear Regression Modelling of Time-Series of Binary Variables in Healthcare. *Comput Math Methods Med.* 2019;2019.
doi:10.1155/2019/3478598
61. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: A tutorial. *Int J Epidemiol.* 2017;46(1):348-355.
doi:10.1093/ije/dyw098
62. Linden A, Arbor A. *Conducting Interrupted Time-Series Analysis for Single-and Multiple-Group Comparisons.* Vol 15.; 2015.
63. Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: Interrupted time series analysis with UK primary care data. *BMJ.* 2016;353.
doi:10.1136/bmj.i3283
64. Lopes EC, Heineck I, Athaydes G, Meinhardt NG, Souto KEP, Stein AT. Is Bariatric Surgery Effective in Reducing Comorbidities and Drug Costs? A Systematic Review and Meta-Analysis. *Obes Surg.* 2015;25(9):1741-1749. doi:10.1007/s11695-015-1777-5
65. Frezza EE, Wathell M, Ewing B. Economic considerations for bariatric surgery and morbid obesity. *Clinicoecon Outcomes Res.* 2009;1:79-83.
<http://www.ncbi.nlm.nih.gov/pubmed/21935309>. Accessed November 6, 2017.
66. BUENO DR, MARUCCI M de FN, GOUVEIA LA, et al. Abdominal obesity and healthcare costs related to hypertension and diabetes in older adults. *Rev Nutr.* 2017;30(2):209-218.
doi:10.1590/1678-98652017000200006
67. Klein S, Ghosh A, Cremieux PY, Eapen S, McGavock TJ. Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI ≥ 35 kg/m². *Obesity (Silver Spring).* 2011;19(3):581-587. doi:10.1038/oby.2010.199
68. Sayeed Ikramuddin, MD; C. David Klingman, PhD; Therese Swan B, and Michael E. Minshall M, Sayeed Ikramuddin M, et al. Cost-Effectiveness of Roux-en-Y Gastric Bypass in Type 2 Diabetes Patients. *Am J Manag Care.* 2009;15(9):607-615.
http://www.ajmc.com/journals/issue/2009/2009-09-vol15-n9/AJMC_sep_Ikramuddin_607to615/. Accessed October 17, 2017.
69. Benraouane F, Litwin SE. Reductions in cardiovascular risk after bariatric surgery. *Curr Opin Cardiol.* 2011;26(6):555-561. doi:10.1097/HCO.0b013e32834b7fc4
70. Vilma Maria JUNGES1, Jarbas Marinho CAVALHEIRO2, Eliana Franzoi FAM2, Vera Elizabeth CLOSS1, João Feliz MORAES3, and Maria Gabriela GOTTLIEB1. Impact of Roux-en-Y Gastric Bypass Surgery (RYGB) on metabolic syndrome components and on the

use of associated drugs in obese patients. *Arq em Gastroenterologia*. doi:10.1590/S0004-2803.201700000-11

71. Borisenko O, Adam D, Funch-Jensen P, et al. Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. *Obes Surg*. 2015;25(9):1559-1568. doi:10.1007/s11695-014-1567-5
72. Doble B, Wordsworth S, Rogers CA, et al. What Are the Real Procedural Costs of Bariatric Surgery? A Systematic Literature Review of Published Cost Analyses. *Obes Surg*. 2017;27(8):2179-2192. doi:10.1007/s11695-017-2749-8